On Thursday, October 17, shares of XORTX Therapeutics, a maker of drugs to treat progressive kidney diseases, plunged over 16% in New York and more than 9% on the in Toronto following the announcement of a $1.5 million registered direct offering. On the Nasdaq, the company’s market capitalization now stands…